SK Biopharmaceuticals Welcomes Proteovant

SK Biopharmaceuticals closes a deal to acquire a 60% stake in Proteovant Therapeutics

Korea, August 14, 2023 – SK Biopharmaceuticals, a global biotech company, announced that the company has completed the acquisition of a 60 percent stake in Proteovant Therapeutics, a U.S. biotechnology company. Following this closure, Proteovant is now part of SK Biopharmaceuticals.

The acquisition allows SK Biopharmaceuticals to leverage Proteovant’s protein degradation capabilities to discover and develop transformative medicines for the treatment of patients with life-altering diseases.

Proteovant was started by Roivant Sciences. SK Inc. retains a 40 percent stake in Proteovant. 

Media Inquiries

SK Biopharmaceuticals & SK Life Science

H. Park, Head of Communications & Global PR

Dina Albanese, Senior Corporate Communications Manager

Hyunkyung Cho, Global PR Manager

skbp_comm@sk.com